Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 2/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.41 |
| ▸ | CDC42BPB | Q9Y5S2 | 2/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 6/20 | 0.37 |
| ▸ | DAGLA | Q9Y4D2 | 6/20 | 0.37 |
| ▸ | PIK3C3 | Q8NEB9 | 4/20 | 0.37 |
| ▸ | DAGLB | Q8NCG7 | 1/20 | 0.37 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | ABHD6 | Q9BV23 | 5/20 | 0.36 |
| ▸ | PRKDC | P78527 | 1/20 | 0.36 |
| ▸ | IGF1R | P08069 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21138256 | 0.87 | ROCK2 (0.41) | ROCK2ROCK1CDC42BPBGBA1ATM | |
| SCHEMBL21057507 | 0.81 | TLR7 (0.36) | TNK2 | |
| SCHEMBL21138748 | 0.81 | NUDT1 (0.39) | ROCK2ROCK1CDC42BPBTNK2 | |
| SCHEMBL21138749 | 0.77 | GBA1 (0.43) | GBA1TNK2PRKDC | |
| SCHEMBL21138230 | 0.77 | ALDH1A1 (0.42) | — | |
| SCHEMBL21138133 | 0.77 | ALDH1A1 (0.42) | — | |
| SCHEMBL21057262 | 0.77 | ALDH1A1 (0.42) | — | |
| SCHEMBL21159348 | 0.76 | MEN1 (0.41) | — | |
| SCHEMBL21138232 | 0.74 | ADORA3 (0.36) | TNK2PIK3C3 | |
| SCHEMBL21138141 | 0.74 | NR1I2 (0.37) | TNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | PDE7B, PDE3A, PDE7A | ROCK2 548/4885ROCK1 279/4885CDC42BPB 1696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.